EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An Anoikis-Based Prognostic Signature Identifies MYC as a Key Regulator of Malignancy and Immunotherapy Resistance in Bladder Cancer

Zhen Tang, Jiao Peng, Xiaoyu Pan, Yuefeng Kong, Haisong Lin, Suchun Wei, Yi Zhan, Siping Zeng

Frontiers in Bioscience-Landmark · 2025

DOI: 10.31083/fbl45386 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2025. Verfasst von Zhen Tang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Fourth Affiliated Hospital of Guangxi Medical University, 545005 Liuzhou, Guangxi, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Proto-Oncogene Proteins c-myc, Anoikis, Drug Resistance, Neoplasm. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangxi Zhuang Autonomous Region Health Commission scientific research project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Resistance to anoikis is a critical mechanism that enables metastatic dissemination. Abrogation of this cellular safeguard is therefore a hallmark of aggressive cancer progression. Despite the importance of anoikis, there are still few biomarkers among anoikis-related genes (ARGs) that could aid in the prognostication of bladder cancer (BC) patients and potentially serve as drug targets.

Methods

This study leveraged bioinformatics analyses of publicly available BC datasets to evaluate the association between differentially expressed ARGs and patient prognosis. Least Absolute Shrinkage and Selection Operator (LASSO) regression analysis was employed to build a novel prognostic signature model for BC based on ARGs. This model was also used to predict the response of BC to anticancer drugs. Additionally, immunohistochemistry was used to assess expression of the key gene, MYC, in BC samples obtained from patients undergoing surgery and from those receiving immune checkpoint inhibitor (ICI) therapy.

Results

The ARG-based signature, developed and validated through the analysis of public databases, was an independent predictor of patient outcomes. Furthermore, it effectively stratified patients into two cohorts (high- and low-risk), allowing investigation of differential drug sensitivities. The risk stratification model identified 10 ARGs (IGF1, CALR, E2F1, MYC, PLK1, SATB1, FASN, ID2, RAC3, and GKN1) as potential therapeutic vulnerabilities. Notably, MYC was identified as a central hub gene within the ARG signature. Elevated MYC expression was strongly associated with worse prognosis in muscle-invasive bladder cancer (MIBC), and with a diminished response to immunotherapy.

Conclusion

This work demonstrated significant prognostic value for the ARG-based model. Specific ARGs could function as crucial biomarkers for patient outcome, while simultaneously offering new avenues for therapeutic intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsProto-Oncogene Proteins c-mycAnoikisDrug Resistance, NeoplasmHumansPrognosisBiomarkers, TumorGene Expression Regulation, NeoplasticMaleFemaleImmunotherapyImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

MYCanoikisbladder cancerimmunohistochemistryimmunotherapy

Substanzen

Proto-Oncogene Proteins c-mycMYC protein, humanBiomarkers, TumorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Urology, The Fourth Affiliated Hospital of Guangxi Medical University, 545005 Liuzhou, Guangxi, China.
  • Department of Radiology, The Fourth Affiliated Hospital of Guangxi Medical University, 545005 Liuzhou, Guangxi, China.
  • Department of Radiology, The First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, China.
  • Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University, 530021 Nanning, Guangxi, China.
  • Center for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, 5300…

Förderung

  • Guangxi Zhuang Autonomous Region Health Commission scientific research project

Zitieren

APA

Tang, Z., Peng, J., Pan, X., Kong, Y., Lin, H., Wei, S., Zhan, Y., & Zeng, S. (2025). An Anoikis-Based Prognostic Signature Identifies MYC as a Key Regulator of Malignancy and Immunotherapy Resistance in Bladder Cancer. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/fbl45386

Vancouver

Tang Z, Peng J, Pan X, Kong Y, Lin H, Wei S, et al. An Anoikis-Based Prognostic Signature Identifies MYC as a Key Regulator of Malignancy and Immunotherapy Resistance in Bladder Cancer. Frontiers in Bioscience-Landmark. 2025. doi:10.31083/fbl45386

BibTeX
@article{Tang2025,
  author = {Tang, Zhen and Peng, Jiao and Pan, Xiaoyu and Kong, Yuefeng and Lin, Haisong and Wei, Suchun and Zhan, Yi and Zeng, Siping},
  title = {An Anoikis-Based Prognostic Signature Identifies MYC as a Key Regulator of Malignancy and Immunotherapy Resistance in Bladder Cancer},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2025},
  doi = {10.31083/fbl45386}
}
Kostenlos starten →